104 related articles for article (PubMed ID: 28410213)
1. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.
Cui M; Gao XS; Gu X; Guo W; Li X; Ma M; Qin S; Qi X; Xie M; Peng C; Bai Y
Oncotarget; 2017 Jun; 8(25):40222-40232. PubMed ID: 28410213
[TBL] [Abstract][Full Text] [Related]
2. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
[TBL] [Abstract][Full Text] [Related]
3. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Risk by BRCA2 Genomic Regions.
Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Tripathi V; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
Eur Urol; 2020 Oct; 78(4):494-497. PubMed ID: 32532514
[TBL] [Abstract][Full Text] [Related]
5. Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
Decker B; Karyadi DM; Davis BW; Karlins E; Tillmans LS; Stanford JL; Thibodeau SN; Ostrander EA
Am J Hum Genet; 2016 May; 98(5):818-829. PubMed ID: 27087322
[TBL] [Abstract][Full Text] [Related]
6. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.
Wedge DC; Gundem G; Mitchell T; Woodcock DJ; Martincorena I; Ghori M; Zamora J; Butler A; Whitaker H; Kote-Jarai Z; Alexandrov LB; Van Loo P; Massie CE; Dentro S; Warren AY; Verrill C; Berney DM; Dennis N; Merson S; Hawkins S; Howat W; Lu YJ; Lambert A; Kay J; Kremeyer B; Karaszi K; Luxton H; Camacho N; Marsden L; Edwards S; Matthews L; Bo V; Leongamornlert D; McLaren S; Ng A; Yu Y; Zhang H; Dadaev T; Thomas S; Easton DF; Ahmed M; Bancroft E; Fisher C; Livni N; Nicol D; Tavaré S; Gill P; Greenman C; Khoo V; Van As N; Kumar P; Ogden C; Cahill D; Thompson A; Mayer E; Rowe E; Dudderidge T; Gnanapragasam V; Shah NC; Raine K; Jones D; Menzies A; Stebbings L; Teague J; Hazell S; Corbishley C; ; de Bono J; Attard G; Isaacs W; Visakorpi T; Fraser M; Boutros PC; Bristow RG; Workman P; Sander C; ; Hamdy FC; Futreal A; McDermott U; Al-Lazikani B; Lynch AG; Bova GS; Foster CS; Brewer DS; Neal DE; Cooper CS; Eeles RA
Nat Genet; 2018 May; 50(5):682-692. PubMed ID: 29662167
[TBL] [Abstract][Full Text] [Related]
7. Case of Basal Cell Carcinoma of the Prostate Successfully Treated Before and After a
Grossman JE; Wu Y; Ye H; Bhatt RS
JCO Precis Oncol; 2018; 2():. PubMed ID: 32914001
[No Abstract] [Full Text] [Related]
8. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
Lecarpentier J; Silvestri V; Kuchenbaecker KB; Barrowdale D; Dennis J; McGuffog L; Soucy P; Leslie G; Rizzolo P; Navazio AS; Valentini V; Zelli V; Lee A; Amin Al Olama A; Tyrer JP; Southey M; John EM; Conner TA; Goldgar DE; Buys SS; Janavicius R; Steele L; Ding YC; Neuhausen SL; Hansen TVO; Osorio A; Weitzel JN; Toss A; Medici V; Cortesi L; Zanna I; Palli D; Radice P; Manoukian S; Peissel B; Azzollini J; Viel A; Cini G; Damante G; Tommasi S; Peterlongo P; Fostira F; Hamann U; Evans DG; Henderson A; Brewer C; Eccles D; Cook J; Ong KR; Walker L; Side LE; Porteous ME; Davidson R; Hodgson S; Frost D; Adlard J; Izatt L; Eeles R; Ellis S; Tischkowitz M; ; Godwin AK; Meindl A; Gehrig A; Dworniczak B; Sutter C; Engel C; Niederacher D; Steinemann D; Hahnen E; Hauke J; Rhiem K; Kast K; Arnold N; Ditsch N; Wang-Gohrke S; Wappenschmidt B; Wand D; Lasset C; Stoppa-Lyonnet D; Belotti M; Damiola F; Barjhoux L; Mazoyer S; ; Van Heetvelde M; Poppe B; De Leeneer K; Claes KBM; de la Hoya M; Garcia-Barberan V; Caldes T; Perez Segura P; Kiiski JI; Aittomäki K; Khan S; Nevanlinna H; van Asperen CJ; ; Vaszko T; Kasler M; Olah E; Balmaña J; Gutiérrez-Enríquez S; Diez O; Teulé A; Izquierdo A; Darder E; Brunet J; Del Valle J; Feliubadalo L; Pujana MA; Lazaro C; Arason A; Agnarsson BA; Johannsson OT; Barkardottir RB; Alducci E; Tognazzo S; Montagna M; Teixeira MR; Pinto P; Spurdle AB; Holland H; ; Lee JW; Lee MH; Lee J; Kim SW; Kang E; Kim Z; Sharma P; Rebbeck TR; Vijai J; Robson M; Lincoln A; Musinsky J; Gaddam P; Tan YY; Berger A; Singer CF; Loud JT; Greene MH; Mulligan AM; Glendon G; Andrulis IL; Toland AE; Senter L; Bojesen A; Nielsen HR; Skytte AB; Sunde L; Jensen UB; Pedersen IS; Krogh L; Kruse TA; Caligo MA; Yoon SY; Teo SH; von Wachenfeldt A; Huo D; Nielsen SM; Olopade OI; Nathanson KL; Domchek SM; Lorenchick C; Jankowitz RC; Campbell I; James P; Mitchell G; Orr N; Park SK; Thomassen M; Offit K; Couch FJ; Simard J; Easton DF; Chenevix-Trench G; Schmutzler RK; Antoniou AC; Ottini L
J Clin Oncol; 2017 Jul; 35(20):2240-2250. PubMed ID: 28448241
[TBL] [Abstract][Full Text] [Related]
9. Next generation mapping reveals novel large genomic rearrangements in prostate cancer.
Jaratlerdsiri W; Chan EKF; Petersen DC; Yang C; Croucher PI; Bornman MSR; Sheth P; Hayes VM
Oncotarget; 2017 Apr; 8(14):23588-23602. PubMed ID: 28423598
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC
Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297
[TBL] [Abstract][Full Text] [Related]
11. The 23rd Annual Prostate Cancer Foundation Scientific Retreat report.
Miyahira AK; Soule HR
Prostate; 2017 Jul; 77(10):1093-1106. PubMed ID: 28503903
[TBL] [Abstract][Full Text] [Related]
12. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
[TBL] [Abstract][Full Text] [Related]
13. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
Sanda MG; Feng Z; Howard DH; Tomlins SA; Sokoll LJ; Chan DW; Regan MM; Groskopf J; Chipman J; Patil DH; Salami SS; Scherr DS; Kagan J; Srivastava S; Thompson IM; Siddiqui J; Fan J; Joon AY; Bantis LE; Rubin MA; Chinnayian AM; Wei JT; ; Bidair M; Kibel A; Lin DW; Lotan Y; Partin A; Taneja S
JAMA Oncol; 2017 Aug; 3(8):1085-1093. PubMed ID: 28520829
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
Conteduca V; Caffo O; Lolli C; Aieta M; Scarpi E; Bianchi E; Maines F; Schepisi G; Salvi S; Massari F; Carrozza F; Veccia A; Chiuri VE; Campadelli E; Facchini G; De Giorgi U
Prostate; 2017 Jun; 77(9):1012-1019. PubMed ID: 28429372
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive review of immunotherapies in prostate cancer.
Maia MC; Hansen AR
Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
[TBL] [Abstract][Full Text] [Related]
16. When should active surveillance for prostate cancer stop if no progression is detected?
de Carvalho TM; Heijnsdijk EAM; de Koning HJ
Prostate; 2017 Jun; 77(9):962-969. PubMed ID: 28419541
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis.
Woo S; Suh CH; Kim SY; Cho JY; Kim SH
Eur Urol; 2018 Jan; 73(1):81-91. PubMed ID: 28412063
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
[TBL] [Abstract][Full Text] [Related]
19. The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening.
Cooperberg MR
Eur Urol; 2017 Sep; 72(3):326-328. PubMed ID: 28535948
[TBL] [Abstract][Full Text] [Related]
20. Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system.
Voigt JD; Dong Y; Linder V; Zappala S
Rev Urol; 2017; 19(1):1-10. PubMed ID: 28522924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
